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While HPV 16 variant lineages have been well characterized, the knowledge about HPV 18 variants is limited. In this study, HPV 18
nucleotide variations in the E2 hinge region were characterized by sequence analysis in 47 control and 51 tumor specimens. Fifty of these
specimens were randomly selected for sequencing of an LCR-E6 segment and 20 samples representative of LCR-E6 and E2 sequence
variants were examined across the L1 region. A total of 2770 nucleotides per HPV 18 variant genome were considered in this study. HPV 18
variant nucleotides were linked among all gene segments analyzed and grouped into three main branches: Asian-American (AA), European
(E), and African (Af). These three branches were equally distributed among controls and cases and when stratified by Hispanic and non-
Hispanic ethnicities. Among invasive cervical cancer cases, no significant differences in the three HPV variant branches were observed
among ethnic groups or when stratified by histopathology (squamous vs. adenocarcinoma). The Af branch showed the greatest nucleotide
variability when compared to the HPV 18 reference sequence and was more closely related to HPV 45 than either AA or E branches. Our data
also characterize nucleotide and amino acid variations in the L1 capsid gene among HPV 18 variants, which may be relevant to vaccine
strategies and subsequent studies of naturally occurring HPV 18 variants. Several novel HPV 18 nucleotide variations were identified in this
study.
D 2005 Elsevier Inc. All rights reserved.Keywords: Papillomavirus; HPV 18; Variants; Oncogenic potential; Vaccine; EthnicityIntroduction
Worldwide, cervical cancer (CC) ranks third among all
cancers in females (9.8%; 371,200 cases per year). In
developing countries it ranks second after breast cancer
(Parkin et al., 1999). In the United States, approximately0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.04.022
i This work was partially presented at the 21st International Papilloma-
virus Meeting in Mexico City; February 22–26, 2004.
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cpeyton@salud.unm.edu (C.L. Peyton), nemartinez@salud.unm.edu
(N. Torrez-Martı´nez), danderson@salud.unm.edu (D.N. Anderson),
cwheeler@salud.unm.edu (C.M. Wheeler).13,000 new cases of invasive CC were expected in 2002,
and approximately 4100 women were expected to die of the
disease (ACS, 2002). Human papillomaviruses (HPV) are
implicated as the causative agents of CC (Bosch et al.,
2002). ‘‘High-risk’’ HPV 16 and HPV 18 are found with the
highest frequencies in CC and account for approximately
two thirds of all cervical carcinomas worldwide (Bosch et
al., 1995). HPV 18 has been associated with a more
aggressive form of cervical intraepithelial neoplasia, inva-
sive CC (adeno- and adenosquamous carcinomas), higher
genome integration rate, and a greater likelihood of cancer
recurrence and lymph node metastasis (Arends et al., 1993;
Barnes et al., 1988; Burk et al., 2003; Burnett et al., 1992;005) 22 – 34
H. Arias-Pulido et al. / Virology 338 (2005) 22–34 23Hildesheim et al., 1999; Kadish et al., 1992; Kurman et al.,
1988; Lizano et al., 1997; Rose et al., 1995; Schwartz et al.,
2001; Walker et al., 1989). In contrast, other studies have
not found such associations (King et al., 1989; Kristensen et
al., 1996; Leminen et al., 1991; van Muyden et al., 1999).
Thus, the role of HPV 18 as a critical determinant of the
course of cervical disease remains controversial, and the
molecular basis underlying the association of different
oncogenic HPV types with malignancy remains unknown.
HPV 16 and HPV 18 show different biochemical and
biological activities from low-risk genital HPV types such
as HPV 6 and HPV 11. For example, the HPV 16 and HPV
18 oncoproteins E6 and E7 bind to p53 and pRB protein,
respectively, with higher affinity than the corresponding
proteins of HPV 6 and HPV 11 (Dyson et al., 1989; Werness
et al., 1990). The HPV 16 and HPV 18 E2 proteins have
intrinsically enhanced potential to activate transcription as
compared to HPV 6 and HPV 11 (Kovelman et al., 1996). In
addition, HPV 16 and HPV 18, but not HPV 6 or HPV 11,
can transform primary keratinocytes in vitro (Durst et al.,
1987; Pirisi et al., 1987; Schlegel et al., 1988), and their E6
and E7 proteins are sufficient and necessary for immorta-
lization of human keratinocytes (Barbosa and Schlegel,
1989; Munger et al., 1989).
Although both HPV 16 and HPV 18 can immortalize
primary human keratinocytes in culture, there are differ-
ences at the molecular level that affect the biologic behavior
of these viruses in the infected epithelia. In particular, HPV
18 has been reported to be more efficient than HPV 16 in
the immortalization of epithelial cells (Barbosa and Schle-
gel, 1989; Romanczuk et al., 1991; Schlegel et al., 1988;
Villa and Schlegel, 1991), and the HPV 18 P105 promoter
was more active than the HPV 16 P97 promoter in primary
human keratinocytes (Romanczuk et al., 1990). The viral
element responsible for the major difference in the
immortalization efficiency of HPV 18 has been mapped to
the transcriptional upstream regulatory region (long control
region; LCR) of the E6 and E7 genes (Romanczuk et al.,
1991; Villa and Schlegel, 1991). Specifically, it was shown
that naturally occurring point mutations in the Sp1 motif
resulted in stronger E6/E7 promoter activity (Rose et al.,
1998), and individual and independent isolates of HPV 18
exhibited different transforming activities in primary human
keratinocytes (Villa and Schlegel, 1991) and cancer cell
lines (Sichero et al., 2005). In addition to differences in the
LCR elements and the viral oncoproteins, nucleotide
variations elsewhere in the HPV 18 viral genome may
affect the transforming potential of this virus.
To date, studies of intra-type variations within the HPV
18 sequences have been limited to the E2 and LCR regions
of the viral genome. A few reports have suggested
associations of HPV 18 variants with a decreased onco-
genic potential (Hecht et al., 1995; Rose et al., 1997),
persistence (Villa et al., 2000), and a defined histological
tumor type (Burk et al., 2003; De Boer et al., 2005; Lizano
et al., 1997).We present here the characterization of HPV 18 variants
and show the linkage of these variants across the LCR, E6,
E2, and L1 regions. The nucleotide and amino acid (aa)
sequence alignments were used to identify variant clusters.
The LCR, E6, and E2 regions were analyzed to determine
the relationship between our variant isolates and those
described previously (Burk et al., 2003; Hecht et al., 1995;
Lizano et al., 1997; Ong et al., 1993; Rose et al., 1997; Terry
et al., 1997; Villa et al., 2000). The L1 region was examined
to determine the prevalence, the extent, and the distribution
of aa changes that might affect immune responses to HPV
18 capsid proteins. These data permit a robust analysis of
HPV 18 phylogeny and demonstrate linkage of genomic
regions not previously reported. In addition, this work
includes the largest HPV 18 variant case–control evaluation
reported to date.Results
Nucleotide sequences of an LCR-E6 fragment (nucleo-
tides 7161 to 317), the E2 coding segment (nucleotides
3482 to 3630), and the L1 coding segment (nucleotides
5458 to 7064) were determined. After analysis of the LCR-
E6, E2, and L1 nucleotide changes, isolates were grouped
into variant classes. Because the major difference in the
immortalization efficiency of HPV 18 has been mapped to
the LCR region upstream of the E6 and E7 genes
(Romanczuk et al., 1991; Villa and Schlegel, 1991), the
LCR-E6 region was analyzed as one block.
Nucleotide sequence variations in the E2 gene were
examined in 98 samples (47 normal and 51 tumors), the
LCR-E6 region in a selected subset of 50 random samples
(38 normal and 12 tumors), and the L1 region in a selected
subset of 20 normal control samples. The selection of L1
samples was based on representation of all major HPV 18
variants identified in either the E2 or LCR-E6 regions. The
LCR-E6, E2, and L1 regions were combined in individual
isolates. Representative variant clusters were identified.
Phylogenetic analysis
Analysis was performed on the LCR-E6 nucleotide
sequence alignment of 1014 nucleotides from all isolates,
including the reference sequence (n = 51). Phylogenetic
analysis of the LCR-E6 segment showed maximal nucleo-
tide diversity between Af and non-African variants and
was the most diverse of all genome regions analyzed (Fig.
1A). The E and AA branches formed two closely related
nodes.
Representative LCR-E6, E2, and L1 sequences from
individual HPV 18 variant isolates were combined, and
these sequences were used to construct an alignment.
Phylogenetic analysis of 2770 nucleotides from each
isolate, including the HPV 18 reference sequence (n =
17), demonstrated that the HPV 18 variants segregate into
Fig. 1. (A) Phylogenetic tree of the HPV 18 LCR-E6 nucleotide sequences that only includes representative variants of AA, E, and Af lineages. The HPV 45
reference sequence is also included in this tree. (B) Linked analysis and resulting phylogenetic tree of the HPV-18 LCR-E6, L1, and E2 nucleotide sequences
from representative variants of AA, E, and Af lineages.
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(Fig. 1B).
HPV 18 LCR and E6 sequence variations
Sequencing of 50 specimens showed patterns of variant
clusters similar to those reported by Ong et al. (1993). We
noted deletions in two regions not examined in that study
(see additional information in Supplementary Table A). AT-C transition at nucleotide position 7592 was observed in
all samples. This nucleotide change was also observed in
the original reference HPV 18 plasmid (kindly provided by
E-M de Villiers, Deutsches Krebsforschungszentrum, Hei-
delberg, Germany), and thus we considered it as a
sequencing error in the original HPV 18 reference sequence
report. Fifteen of 50 (30%) isolates that presented 0 to 4
randomly distributed nucleotide variations belonged to the
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only one sample (see additional information in Supple-
mentary Table A). Twenty-four of 50 (48%) isolates
clustered in the E branch. Within the E branch, randomly
distributed nucleotide variations (n = 4–12) were observed
but a few of these nucleotide alterations were common
among the isolates. Changes at nucleotide positions 7258,
7567, 7670, and 104 were found in all E branch samples.
Changes at nucleotide positions 7486, 7529, and 7563 were
observed in 75%, 87.5%, and 54.2% of the E branch
isolates, respectively. Nucleotide variation at positions
7164, 7184, and 7283 were each observed in 16.7% of
the samples. Eleven of 50 (22%) isolates belonged to the Af
branch. The greatest number of nucleotide changes (n =
21–24) was observed in the Af branch. The most common
Af branch nucleotide variations were found at 22 positions.
Twenty of these variations were found in all isolates at
nucleotide positions 7161, 7164, 7185, 7258, 7323, 7496,
7512, 7529, 7530, 7563, 7567, 7643, 7651, 7658, 7670,
7704, 7726, 7730, 92, and 266. As noted earlier, nucleotide
changes at 7258, 7567, and 7670 were also found in all E
branch isolates. Two other common variant nucleotide
positions were observed in Af branch samples at nucleotide
positions 251 (9 of 11 isolates; 82%) and 317 (5 of 11
isolates; 45%). In addition, we found a 7-nucleotide
deletion that spans nucleotides 7245 to 7251 in all Af
branch isolates. Single nucleotide variations were found
randomly distributed in three samples (see additional
information in Supplementary Table A). Seven nucleotide
variations that are included within nucleotide positions
7161 to 7323, as well as deletions at 7245–7251 and
7373–7387 have not been previously reported.
Overall, for the 1013-bp LCR-E6 fragment, the maxi-
mum deviation between any two isolates was 24 nucleo-
tides, a variability of 2.4%. Representative HPV 18 LCR
and E6 sequence variations are included in Fig. 2.
HPV 18 E2 sequence variations
Representative HPV 18 E2 sequences are included in
Fig. 2 (see additional information in Supplementary Table
B). HPV 18 E2 variant isolates segregated into three main
clusters. The first cluster represented 25 isolates with either
no nucleotide changes (n = 20; 80%), one nucleotide change
(n = 4; 16%), or three randomly distributed nucleotide
changes (n = 1; 4%). This cluster resembled the HPV 18
reference sequence that belongs to the AA branch. The
second cluster was formed by 64 isolates that contained a
single C-G transversion at position 3630 with no additional
nucleotide changes (n = 43; 67%) or in a few cases, 1 to 3
random nucleotide changes (n = 21; 33%). Within this
cluster, in addition to the fixed C-G transversion, we
observed a G-A transition at nucleotide 3482, and a T-A
transversion at nucleotide 3492 that were in 14% and 12.5%
of the isolates, respectively (Fig. 2). This cluster formed the
E branch. The third cluster contained 5 nucleotide changesat positions 3534, 3558, 3578, 3586, and 3593 that were
observed in all 9 isolates. The presence of the C-G
transversion at position 3630 was observed in 55.5% of
isolates (n = 5 of 9). This cluster formed the Af branch.
Nucleotides changes at positions 3547, 3573, 3581, 3584,
3595, and 3613 have not been previously reported. These
changes were identified only once each in six isolates.
Overall, for the 149-bp E2 fragment, the maximum
deviation between any two isolates was 6 nucleotides, a
variability of 4%.
The distribution of the HPV 18 E2 variants in controls
and cases was not significantly different: the AA branch
isolates were found in 25.5% (n = 12) of controls and
25.5% (n = 13) of cases; E branch isolates were found in
66.0% (n = 31) of controls, and 64.7% (n = 33) of cases; Af
branch isolates were found in 8.5% (n = 4) of controls and
9.8% (n = 5) of cases. HPV 18 E2 variants were also not
significantly different by ethnicity: AA branch isolates were
identified in 26.1% and 25.0%; E branch isolates in 63.0%
and 67.3%, and Af branch isolates in 10.9% and 7.8% of
Hispanics and non-Hispanic whites, respectively.
The distribution of HPV 18 E2 variants was compared by
histopathology in 25 invasive cancers (15 squamous cell
carcinomas and 10 adenocarcinomas). The distribution was
as follows: the AA, E, and Af branch isolates were found in
26.7% (n = 4) and 30% (n = 3); 60% (n = 9) and 60% (n =
6); 13.3% (n = 2) and 10% (n = 1) of squamous cell and
adenocarcinoma, respectively. The differences were not
significant. The AA, E, and Af branch isolates did not
differ by ethnicity in these 25 cases and were found in
42.9% (n = 3) and 22.2% (n = 4); 42.9% (n = 3) and 66.7%
(n = 12); 14.3% (n = 1) and 11.1% (n = 2) of Hispanics and
non-Hispanic whites, respectively. When the variants were
classified as European vs. non-European (AA and Af
grouped together) there was still no significant difference
by histopathology or ethnicity, although the presence of
European variants was higher in non-Hispanic whites than
in Hispanics (66.7% vs. 42.9%).
Intra-type amino acid (aa) variation in HPV 18 E2 and E4
At the protein level, aa changes in E2 protein were
observed in all three phylogenetic branches with the highest
number of aa changes in the Af branch (Fig. 2). The AA
branch presented changes at aa 217 (alanine to threonine) and
aa 224 (serine to leucine) as a result of the G-A transition at
nucleotide 3525 and C-T transition at nucleotide 3547,
respectively. These changes were only observed once each
in a single isolate. The aa change that results from the
nucleotide variation at position 3547 has not been previously
reported. The E branch isolates showed two aa changes at
residues 206 (serine to threonine) and 252 (proline to alanine)
that resulted from the T-A and the C-G transversions at
nucleotides 3492 and 3630, respectively (Fig. 2). Both of
these changes were observed in several isolates. Nucleotide
changes at 3534 (T-C), 3586 (A-C), 3593 (T-G), 3630 (C-G)
H. Arias-Pulido et al. / Virology 338 (2005) 22–3426in the Af branch gave four aa changes at residues 220
(tyrosine to histidine), 237 (lysine to threonine), 239
(histidine to glutamine), and 252 (proline to alanine),
respectively (Fig. 2).
The E4 protein demonstrated aa changes only in the E
and Af branches. In the E branch, the G-A, and T-C
transitions at nucleotides 3482, 3563, and C-G trans-
version at nucleotide 3630 gave aa changes in residue 22
(serine to asparagine), 49 (leucine to proline), and 71
(histidine to glutamine), respectively. The changes at
residues 22 and 49 were observed once in single isolates,
and the change at residue 71 was detected in numerous
isolates. Nucleotide changes observed at 3558 (C-A),
3578 (C-T), 3586 (A-C), 3593 (T-G), and 3630 (C-G)
generated five aa changes at residues 47 (histidine to
glutamine), 54 (serine to leucine), 57 (serine to arginine),
59 (isoleucine to serine), and 71 (histidine to glutamine)Fig. 2. Nucleotide sequence variations among the HPV 18 isolates. LCR-E6, E2,
across the top. The identification codes of the samples are indicated along the far l
samples obtained from women with normal cervices. Phylogenetic groupings based
right column. X denotes nucleotide positions at which multiple replacements occur
are shown below the line. For nucleotide and amino acid variations, positions that
Empty spaces indicate absence of the nucleotide sequence data.in the Af branch (Fig. 2). All five changes were observed
in all Af branch isolates.
Sequence variations within the HPV 18 L1 region
The L1 region was amplified and sequenced from 26
control subjects (see additional information in Supplemen-
tary Table C). These specific samples were selected to
represent the predominant HPV 18 variants observed in the
LCR-E6 and E2 regions. Representative HPV18 L1 sequen-
ces are included in Fig. 2. It should be noted that none of the
HPV 18 specimens analyzed contained the previously
reported HPV 18 reference sequence. All 26 of the HPV 18
specimens analyzed had four C-G transversions at positions
5701, 6460, 6625, and 6842 which have been previously
reported as errors in the original sequence (Meissner, 1997).
AG-A transition was observed in all isolates at position 5503.
This change was not found in the reference HPV 18 clone.and L1 positions at which variations were observed are indicated vertically
eft column. Specimen’s identifiers (IDs) are designated with L and represen
on analysis of the LCR-E6, E2, and L1sequence are indicated along the fa
red. Amino acid variations among these isolates in the E2, E4, and L1 ORF
do not vary relative to the HPV reference sequence are marked with dashest
r
.
Fig. 2 (continued ).
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E6 isolates into three main clusters: the AA branch isolates
that showed 1 or 2 nucleotide change were found in 8 of the
26 (30.8%) isolates. The E branch isolates showed 4 to 6
nucleotide changes. Four of these variations at nucleotides
5503, 5619, 5875, and 6401 were present in 14 of 15
isolates (93.3%). One sample (L2574) demonstrated a
double signal (A/G) at position 5581, suggesting a mixed
population of HPV 18 genomes in this clinical specimen.
The reference (G) and the variant (A) sequence were both
detected (Fig. 2; Supplementary Table C).
The Af branch isolates showed the greatest number of
nucleotide changes which ranged from 18 to 20 in 3 of the 26
(11.5%) isolates. As a characteristic of the Af branch,
nucleotide changes were fixed in 18 nucleotide positions at
nucleotides 5503, 5581, 5584, 5648, 5684, 5832, 5875, 6017,
6185, 6401, 6579, 6581, 6626, 6719, 6749, 6917, 6986, and
7064 (Fig. 2; Supplementary Table C).
Overall, for the 1606-bp L1 fragment, the maximum
deviation between any two isolates was 20 nucleotides, a
variability of 1.2%. Seventeen nucleotide variations, encom-passing regions 5458–6430, and three at 7025, 7037, and
7064 are novel HPV 18 L1 nucleotide variants.
Intra-type aa variation in HPV 18 L1
At the protein level for L1, aa changes were observed in
the E and Af branches (Fig. 2). The E branch isolates
showed seven aa changes at residues 10 (leucine to serine),
48 (leucine to phenylalanine), 51 (arginine to lysine), 64
(leucine to methionine), 149 (threonine to asparagine), 163
(alanine to valine), and 334 (glutamine to proline). These aa
changes resulted from changes at nucleotides 5458 (T-C),
5573 (A-C), 5581 (G-A), 5619 (T-A), 5875 (C-A), 5920 (C-
T), and 6430 (A-C), respectively (Fig. 2). The Af branch
isolates showed six aa changes at residues 51 (arginine to
lysine), 52 (asparagine to serine), 116 (glycine to serine),
149 (threonine to asparagine), 384 (valine to isoleucine),
and 505 (lysine to arginine) as a result of changes at
nucleotides 5581 (G-A), 5584 (A-G), 5775 (G-A), 5875 (C-
A), 6579 (G-A), and 6943 (A-G) (Fig. 2). These results
extended our previously reported data about nucleotide and
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and report 9 new aa changes in HPV 18 L1 region.
Linkage of HPV 18 sequence variants
Alignment of the LCR-E6, E2, and L1 sequences showed
a segregation of variants. These linked regions allowed
classification of the variants as AA, E, and Af. Isolates of
the AA variants showed 0 to 3 random nucleotide changes
in the LCR-E6 region, 0 to 3 nucleotide changes in the E2
region, and 0 to 1 nucleotide change in the L1 region. The E
variants showed common, ‘‘fixed’’ alterations across LCR-
E6 and L1. In contrast to the AA and E variants, the Af
variants showed fixed alterations across the LCR-E6, E2,
and L1 segments (Fig. 2).
Using the LCR-E6 and L1 linked segment, it was
possible to classify one sample (L2574) that had a partial
Af E2 sequence, as an E-related variant. Also, sample
L2380 shared the fixed presence of the E2 C-G change at
nucleotide 3630, which was otherwise only detected in E
branch samples. The LCR-E6 and L1 linked analyses
defined L2380 as a member of the AA branch (Fig. 2).
Sequence alignment of HPV 18 and HPV 45 variants
HPV 45 is the closest relative of HPV 18 (Chan et al.,
1992a). Table 1 shows a partial genomic alignment of a
1013-bp fragment from the HPV 18 reference clone, the
HPV 18 variants identified in this study and the equivalent
genome segment from the HPV 45 reference clone (Reuter
et al., 1991) (GenBank accession no. X74479). The analysis
of the overlapping sequences of HPV 18 (nucleotide
positions 7161–317) and HPV 45 (nucleotide positions
7191–314) showed the presence of 10 deletions that ranged
from 1 to 21 nt and a 3-bp insertion in the HPV 45
nucleotide sequence. Nevertheless, the nucleotide alignment
showed that HPV 18 differs from HPV 45 by 195 (19.2%)
nucleotide positions in this 1013 bp fragment. The HPV 18
Af isolates showed 11 nucleotides changes identical to the
HPV 45 reference sequence whereas the HPV 18 AA and ETable 1
Alignment of the HPV 18 (1013 bp) reference sequence, HPV 18 representative
HPV 18 reference
sequence
7161 7164 7258 7283 7323 7486 7496 7512 7529 7563 7
C C T A A C C G C G A
L 0990 – – – – – – – – – – –
L 2380 – – – T – – – – – – –
L 1703 – – – – – – – – A – –
L 2207 – – A – – T – – A A C
L 0531 – A A – – T – – A A C
L 2574 – A A T – T – – A A C
L 1557 T G A – G – G A A A C
L 2247 T G A – G – G A A A C
IS 802 T G A – G – G A A A C
HPV 45 reference
sequence
T G C A T G A A C A T
7197 7200 7294 7314 7349 7506 7516 7531 7548 7561 7
The identification codes of the samples are indicated along the far left column. P
sake, selected samples are shown and deletion/insertions not related to variants aisolates showed 1 to 2 nucleotide changes, respectively, that
were shared with the HPV 45 reference sequence.Discussion
In this study, we describe the HPV 18 intra-type diversity
over a span of 2770 nucleotide bases among isolates from
the United States. In addition, we present the linked LCR-
E6, E2, and L1 sequences of HPV 18 variants. The data set
complements and expands previous descriptions of HPV 18
variants based on targeted analysis of E2 and LCR-E6
regions (Burk et al., 2003; Hecht et al., 1995; Lizano et al.,
1997; Ong et al., 1993; Rose et al., 1997; Terry et al., 1997;
Villa et al., 2000).
Nucleotide signatures for AA, E, and Af HPV 18
lineages were clearly defined for LCR-E6 and L1 sequen-
ces. These regions showed, as a main feature, fixed
variations in more than one position. This feature was not
observed in the E2 region. Within the E2 region, only the Af
branch could be clearly distinguished. Thus, classification of
the HPV 18 variants by E2 sequences is less informative
than by LCR-E6 and L1 sequences. The linkage of HPV 18
E2 with other genomic segments has not been reported
previously.
This catalog of HPV 18 nucleotide signature positions
could be used to develop lineage-specific oligonucleotide
probes to assist future large-scale epidemiological studies of
HPV 18 infections. Specifically, we found that a fragment of
the LCR (nucleotides 7567 to 7670; 103 bp) or L1 region
(nucleotides 5832 to 6401; 569 bp) is capable of distin-
guishing all HPV 18 lineages.
Similar to the analysis of HPV 16 variants (Chan et al.,
1992b; Icenogle et al., 1991; Yamada et al., 1995),
nucleotide changes present in the HPV 18 LCR-E6, E2,
and L1 segments were phylogenetically compatible. The
isolates that we have examined did not appear to be the
products of genetic recombination between viruses ofvariant sequences, and the HPV 45 (981 bp) reference sequence
567 7643 7651 7658 7670 7704 7726 7730 92 104 251 266 317 Var.
T T A A T C C A T T G T
– – – – – – – – – – – – AA
– – – – – – – – – – – – AA
– – – – – – – – – – – – AA
– – – T – – – – C – – – E
– – – T – – – – C – – – E
– – – T – – – – C – – – E
G C C T C T A G – – A – Af
G C C T C T A G – C A – Af
G C C T C T A G – C A C Af
G C A T C T A A G T A T
565 7641 7649 7656 7668 7702 7724 7728 89 101 248 263 314
hylogenetic groupings are indicated along the far right column. For clarity
re not displayed.
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L2574 isolate that was classified as an E variant but which
had partial Af sequences in the E2 region. The fact that
recombination between variants of HPV 18 is rare or
nonexistent implies that nucleotide changes in one region
can be used as markers of changes found in other regions
within the same lineage (Yamada et al., 1995). Thus, we
classified the HPV 18 variants as proposed by Ong et al.
(1993) for the LCR region and extended this classification
to other genome segments.
The data presented here permit good resolution of certain
details of the HPV 18 phylogenetic tree shown in Fig. 1A.
As with previous phylogenetic analyses based on LCR and
L1 variations (Ong et al., 1993; Stewart et al., 1996), we
find that the majority of nucleotide variations separate the
Af class from the E and AA branches. The addition to the
LCR-E6 region of the E2 and L1 segments did not change
the clustering of the HPV 18 variants (Fig. 1B).
The HPV major capsid protein encoded by the L1 ORF is
the target of neutralizing antibody responses (Kirnbauer
et al., 1992; Roden et al., 1994a,b), and naturally
occurring L1 antibodies react almost exclusively with
conformation-dependent epitopes (Kirnbauer et al., 1994).
Although the HPV L1model proposed byModis et al. (2002)
postulated that the L1 C-terminal is exposed on the viral
surface, and is therefore expected to be highly antigenic, the
location or structures of the epitopes with which L1
antibodies react remain unknown for HPV 18. L1 hyper-
variable regions lie on the outward-facing surface of the
pentamer (Modis et al., 2002), thus a challenge will be to
determine whether intra-type HPV 18 variants are relevant to
HPV vaccine strategies. In addition, the effects of HPV 18 aa
variations on other immune response pathways occurring
during natural infection should be considered.
In an extensive analysis of HPV 16 variants, we found
that the prevalence of multiple HPV-16 variant infection
was quite uncommon (0.7%) (Yamada et al., 1997). We and
others have reported that HPV-16 establishes a persistent
infection in which a single HPV variant is either detected or
predominates, and co-infection with addition HPV-16
variants whenever rarely detectable results in a minor
population of HPV-16 genomes (Mayrand et al., 2000;
Wheeler et al., 1997; Yamada et al., 1997). Other published
reports have similarly demonstrated that detection of mixed
HPV variant infections for HPV 31, 33, 35, and 52 are either
never observed or uncommon (Aho et al., 2004; Gagnon et
al., 2004, 2005). Our data are similar for HPV 18 variants.
We detected multiple HPV 18 co-infections in only 1% (1 of
98) of samples. We have conducted studies on the sensi-
tivity of detecting mixed variant infections including re-
construction experiments. Our methods as well as all
existing methods that we are aware of only have the ability
to theoretically measure variants represented by 20% of a
total single genotype under evaluation (Emeny et al., 1999).
Given this limitation, it is possible that mixed HPV 18
variant infections were present or that variant infectionswere represented by rare integration events with an addi-
tional HPV 18 variant; however, our methods were unable
to address this issue. Our data are however consistent with
detecting genomic segments that are phylogenetically com-
patible and derived from a single HPV 18 variant infection.
The non-coding HPV 18 LCR segment contains a large
number of cis-responsive elements that control HPV 18
gene expression and replication (Bernard, 2000). The
fragment has been divided in three parts: the 5V segment
that contains the transcription termination signal; the central
segment, flanked by E2 binding sites 4 and 3 (E2BS4,
E2BS3) which contains the majority of epithelial specific
enhancers; and the 3Vsegment, bracketed by E2BS3 and the
E6 gene start, contains the origin of replication and the E6/
E7 promoter (Bernard, 2000). The immortalization and
transforming features of HPV 18 have been related to this
genome region (Rose et al., 1997, 1998; Villa and Schlegel,
1991), and it is possible that nucleotide variations in the
LCR-E6 segment may affect the HPV 18 transformation and
oncogenic properties (Rose et al., 1998; Sichero et al.,
2005).
We have found that LCR variations cluster within its
central segment (nucleotides 7486 to 7742; Fig. 2). This
nucleotide variability may affect transcription factor binding
sites such as Tef-1, YY1, NFI, AP-1, and Oct-1. In the
promoter region, the observed nucleotide variability may
affect the YY1 binding site, located at position nucleotide
79 (Bernard, 2000). Whether this nucleotide variation may
have an effect on the biological behavior of HPV 18-
associated lesions remains unknown. Two studies demon-
strated that nucleotide variations at nucleotide positions 41
and 104 resulted in higher E6/E7 promoter activity by
modulating the Sp1 and YY1 transcription factors (Rose et
al., 1997, 1998). Further, it was suggested that patients with
the nucleotide variation at 104 (T-C) were less likely to
present tumor recurrence than patients with the reference
sequence (Rose et al., 1997). Interestingly, a closer
examination of those HPV 18 variants using our linked
HPV 18 variant analysis indicates that the HPV 18 reference
variant, presented in recurrent tumors, belongs to the AA
lineage while the HPV 18 variant with a T-C transition at
nucleotide 104 belongs to the E lineage.
In addition to transcription termination signals, the 5V
segment contains a matrix attachment region, located
roughly between positions 7150 to 7450 (Tan et al.,
1998), which plays a critical role in transcriptional
modulation. The common 7-bp deletion found in all Af
branches lies in this 5Vsegment.
The activities of the epithelial specific enhancer, the E6
promoter, as well as the activity of a large LCR segment at
the 5Vend depend on several different transcription factors
(Ai et al., 1999; Bernard, 2000; O’Connor et al., 1995; Tan
et al., 1998). One can suggest that the observed nucleotide
variations and deletions in the HPV 18 LCR may effect the
functioning of this region and hence affect the biologic
function of HPV 18 variants.
H. Arias-Pulido et al. / Virology 338 (2005) 22–3430In striking contrast to the HPV 16 E6 region which
showed high nucleotide variation at the 5V end (Yamada
et al., 1995), the HPV 18 E6 fragment did not show
nucleotide variability in this region and no aa changes
were observed. This difference in the nucleotide variation
between these viral types may, in part, explain differences
in the biologic behavior of these viruses (Barbosa and
Schlegel, 1989; Romanczuk et al., 1991; Schlegel et al.,
1988; Villa and Schlegel, 1991). Further, these findings
indicate that although HPV 16 and HPV 18 as well as
other HPV types demonstrate linked nucleotide changes
between genome segments, variations may be localized
within different regions even within the same ORF.
Hence, functional and even epidemiologic studies will
need to consider that different HPV types may need
distinct approaches and considerations.
It has been shown that the HPV 18 E2 protein
differentially modulates transcription and DNA replication
(Steger and Corbach, 1997). While low levels of E2 will
activate the promoter by binding to the E2BS4 to
generate early proteins, including E2, increasing amounts
of E2 will bind to E2BS3, 2, and 1, leading to repression
of transcription by the early promoter and, in parallel, to
activation of viral DNA replication (Kim et al., 2000;
Steger and Corbach, 1997). Whether the observed
nucleotide variations both in the enhancer and promoter
LCR affect the E2 binding process is unknown. Nucleo-
tide variations in the LCR region may affect the
occupancy of the E2BS sites and the repression of E6/
E7 oncoproteins. It is believed that deregulation of E6/E7
gene expression is a landmark in cancer progression
(Mantovani and Banks, 2001; Munger et al., 2001).
Although nucleotide variability in the E2 segment was
less than that found in the L1 and LCR segments, it is
possible that the aa changes, resulting from the nucleotide
variation, may affect some properties of HPV 18 E2
associated with viral transcription and DNA replication.
Defining the biological meaning of these alterations is not
straightforward. In one study, the existence of a subtype
with a decreased oncogenic potential has been proposed
(Hecht et al., 1995). A comparison of the HPV 18 E2
nucleotide variation in that report with our results showed
that those variant isolates belong to the Af lineage.
However, we found no difference in the distribution of
this HPV 18 variant in control and case isolates (44.5%
vs. 55.5%; P > 0.05). Thus, the proposed HPV 18
subtype belongs to the Af branch but its decreased
oncogenic potential was not supported by our study. In
addition, we found no difference in the distribution of
HPV 18 variants when comparing squamous cell carci-
nomas with adenocarcinomas. Our data do not support
the proposed association of non-European variants (spe-
cifically the AA variant) with adenocarcinoma as sug-
gested by other groups (Burk et al., 2003; De Boer et al.,
2005; Lizano et al., 1997). Differences in our findings
and those of other investigators may be due to differ-ences in study designs and the relatively small sample
sizes.
It is worth noting that nucleotide sequences were
determined for the HPV 18 E2 hinge region in all 51
cervical cancer specimens included in this study. The
majority of reports indicate that integration of the HPV 16
viral genome take place more frequently in the HPV 16 E2
hinge region (nucleotides 3338 to 3571) (Cullen et al., 1991;
Kalantari et al., 1998; Vernon et al., 1997). Alignment of
HPV 16 and 18 E2 genes shows that the HPV 18 E2 region
analyzed in this study is similar to the HPV 16 E2 hinge
region (data not show). A few reports have shown deletions
at E1/E2 regions in invasive cancers (Berumen et al., 1994;
Corden et al., 1999; Cullen et al., 1991; Kitagawa et al.,
1996). If strictly integrated HPV 18 genomes represent any
significant proportion of invasive cancers, it may be
unlikely that the integration event occurs commonly within
the HPV 18 E2 hinge region. Alternatively, it is more likely
that HPV 18 integration events exist in the presence of
hundreds to thousands of viral episomes and that strict
integration is uncommon.
The E4 ORF is contained completely within the E2 ORF.
It has been suggested that E4 plays a role in productive
infection, virus maturation, and interaction with cellular
keratins to increase the fragility of the infected cell (Doorbar
and Myers, 1996). The knowledge of the role of E4 in the
virus life cycle is limited. E4 gene products are found
primarily in the cytoplasm of superficial keratinocytes,
where they are reported to induce collapse of the cytokeratin
matrix (Doorbar, 1991). We found nucleotide variations that
lead to aa changes in the E4 ORF in two isolates of the E
branch. All Af isolates presented six aa changes (Fig. 2).
Whether the reported aa variations in the E4 ORF affect the
biological function of E4 remains unknown.
Our data set provides information supporting the genetic
linkage of various HPV 18 genomic regions, the potential of
selection pressures shared between genomic regions, and
introduces several novel HPV 18 nucleotide variations.
These and previous data also support the hypothesis that
HPV 18 and HPV 45 are derived from a potential common
ancestor. Moreover, these data form a basis for considering
HPV 18 sequence variations in HPV 18 L1-based vaccine
strategies, as correlates of cervical disease risk in natural
history studies, and as tools for studying epidemiological
correlates such as viral persistence, transmission, and
oncogenic potential.Materials and methods
Clinical specimens
Cervical swab specimens (controls; n = 47) and
paraffin-embedded biopsies (tumors; n = 51; 26 carci-
noma in situ; 25 invasive CC) collected from subjects
enrolled in epidemiologic investigations conducted in
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H. Arias-Pulido et al. / Virology 338 (2005) 22–34 31Albuquerque, NM, USA, were utilized in this study
(Peyton et al., 2001). Controls had no past or current
history of cervical abnormalities. Twelve invasive cervical
cancer cases from the International Biology Study (IS
samples) were also included in the phylogenetic analyses
(Stewart et al., 1996). The distribution of the ethnic
groups from the U.S. study was as follows: control
group, 32 Hispanics and 25 non-Hispanic whites;
carcinoma in situ group, 13 Hispanics and 13 non-
Hispanic whites; CC group, 7 Hispanics and 18 non-
Hispanic whites.
HPV18 nucleotide position numbering
HPV18 DNA nucleotide positions are numbered accord-
ing to the published sequence of the reference clone (Cole
and Danos, 1987) (GenBank accession no. X05105), revised
to include corrections previously reported (Meissner, 1997).
PCR
The LCR-E6, E2, and L1 regions were amplified by PCR
using the primers and conditions shown in Table 2. An
initial denaturation step of 10 min at 94 -C and a final
extension of 10 min at 72 -C were included in each PCR.
Each 100 Al PCR contained 2.5 mM MgCl2, 200 AM
dNTPs, 5U Taq Gold polymerase, and 10 pmol primers.
Two microliters of the PCR product obtained with the outer
primer pairs were used as template for amplification with
the inner primer pairs. Amplicons were visualized on 0.8%
agarose gels stained with ethidium bromide.
Sequence and phylogenetic analyses
All sequencing was performed at the University of New
Mexico Center for Genetics in Medicine. PCR amplicons
were diluted 1:20 in distilled water and sequenced with 1.6
AM primer (forward or reverse). Nucleotide variations were
accepted only when they were reproducible from a second
PCR amplification. This strategy has been used previously
for the identification of HPV16 molecular variants (Chan
et al., 1992b; Pushko et al., 1994).
Sequence contigs were aligned to generate a consensus
sequence using Genetic Computer Group (GCG; Madison,
WI) Fragment Assembly System. Regions of nucleotide
misalignments or ambiguity were resolved by reviewing
DNA sequencing traces, or by re-sequencing when neces-
sary. HPV18 consensus sequences for each region (LCR-E6,
E2, L1) were aligned using ClustalX, as were derived aa
sequences (Thompson et al., 1997). 1014 or 2770 nucleo-
tides were used for the LCR-E6, or the LCR-E6-E2-L1
multiple sequence alignments, respectively. Phylogenetic
analyses were conducted using the neighbor joining method
(Saitou and Nei, 1987). The unrooted phylogenetic tree was
displayed using the UNROOTED program included with
CLUSTAL_X.
H. Arias-Pulido et al. / Virology 338 (2005) 22–3432Nucleotide-sequence accession numbers
The nucleotide sequences of unique HPV 18 LCR-E6,
E2, and L1 variants have been entered into GenBank with
the accession numbers AY863151–AY863191.Acknowledgments
The authors want to acknowledge Dr. E-M de Villiers,
Krebsforschungszentrum, Heidelberg, Germany, for kindly
providing us with the reference HPV 18 plasmid, and C.
Hunt (Department of Epidemiology, UNM) for technical
help with statistical analyses. This study was supported by
CA/AI32917, a grant from the NIH to CMW.Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.virol.2005.
04.022.References
ACS, 2002. Cancer Facts and Figures 2002. American Cancer Society,
Atlanta, GA.
Aho, J., Hankins, C., Tremblay, C., Forest, P., Pourreaux, K., Rouah, F.,
Coutlee, F. 2004. Genomic polymorphism of human papillomavirus
type 52 predisposes toward persistent infection in sexually active
women. J. Infect. Dis. 190, 46–52.
Ai, W., Toussaint, E., Roman, A. 1999. CCAAT displacement protein binds
to and negatively regulates human papillomavirus Type 6 E6, E7, and
E1 promoters. J. Virol. 73, 4220–4229.
Arends, M., Donaldson, Y., Duvall, E., Wyllie, A., Bird, C. 1993. Human
papillomavirus type 18 associates with more advanced cervical neo-
plasia than human papillomavirus type 16. Hum. Pathol. 24, 432–437.
Barbosa, M., Schlegel, R. 1989. The E6 and E7 genes of HPV-18 are
sufficient for inducing two-stage in vitro transformation of human
keratinocytes. Oncogene 4, 1529–1532.
Barnes, W., Delgado, G., Kurman, R., Petrilli, E., Smith, D., Ahmed, S.,
Lorincz, A., Temple, G., Jenson, A., Lancaster, W. 1988. Possible
prognostic significance of human papillomavirus type in cervical
cancer. Gynecol. Oncol. 29, 267–273.
Bernard, H.-U. 2000. Regulation of human papillomavirus gene expression
by the factor DP, nucleosomes and the nuclear matrix. Papillomavirus
Rep. 11, 73–80.
Berumen, J., Casas, L., Segura, E., Amezcua, J., Garcia-Carranca, A. 1994.
Genome amplification of human papillomavirus types 16 and 18 in
cervical carcinomas is related to the retention of E1/E2 genes. Int. J.
Cancer 56, 640–645.
Bosch, F., Manos, M., Munoz, N., Sherman, M., Jansen, A., Peto, J.,
Schiffman, M., Moreno, V., Kurman, R., Shah, K. 1995. Prevalence of
human papillomavirus in cervical cancer: a worldwide perspective.
International Biological Study on Cervical Cancer (IBSCC) Study
Group. J. Natl. Cancer. Inst. 87, 796–802.
Bosch, F.X., Lorincz, A., Munoz, N., Meijer, C.J.L.M., Shah, K.V. 2002.
The causal relation between human papillomavirus and cervical cancer.
J. Clin. Pathol. 55, 244–265.
Burk, R.D., Terai, M., Gravitt, P.E., Brinton, L.A., Kurman, R.J., Barnes,
W.A., Greenberg, M.D., Hadjimichael, O.C., Fu, L., McGowan, L.,Mortel, R., Schwartz, P.E., Hildesheim, A. 2003. Distribution of human
papillomavirus types 16 and 18 variants in squamous cell carcinomas
and adenocarcinomas of the cervix. Cancer Res. 63, 7215–7220.
Burnett, A., Barnes, W., Johnson, J., Grendys, E., Willett, G., Barter, J.,
Doniger, J. 1992. Prognostic significance of polymerase chain reaction
detected human papillomavirus of tumors and lymph nodes in surgically
treated stage IB cervical cancer. Gynecol. Oncol. 47, 343–347.
Chan, S., Bernard, H., Ong, C., Chan, S., Hofmann, B., Delius, H. 1992a.
Phylogenetic analysis of 48 papillomavirus types and 28 subtypes and
variants: a showcase for the molecular evolution of DNA viruses.
J. Virol. 66, 5714–5725.
Chan, S., Ho, L., Ong, C., Chow, V., Drescher, B., Durst, M., ter Meulen, J.,
Villa, L., Luande, J., Mgaya, H. 1992b. Molecular variants of human
papillomavirus type 16 from four continents suggest ancient pandemic
spread of the virus and its coevolution with humankind. J. Virol. 66,
2057–2066.
Cole, S., Danos, O. 1987. Nucleotide sequence and comparative analysis of
the human papillomavirus type 18 genome. Phylogeny of papillomavi-
ruses and repeated structure of the E6 and E7 gene products. J. Mol.
Biol. 193, 599–608.
Corden, S., Sant-Cassia, L., Easton, A., Morris, A. 1999. The
integration of HPV-18 DNA in cervical carcinoma. Mol. Pathol. 52,
275–282.
Cullen, A., Reid, R., Campion, M., Lorincz, A. 1991. Analysis of the
physical state of different human papillomavirus DNAs in intraepithelial
and invasive cervical neoplasm. J. Virol. 65, 606–612.
De Boer, M., Peters, L.A., Aziz, M., Siregar, B., Cornain, S., Vrede, M.,
Jordanova, E., Fleuren, G. 2005. Human papillomavirus type 18
variants: histopathology and E6/E7 polymorphisms in three countries.
Int. J. Cancer 114, 422–425 (See errata in Int. J. Cancer 114, 1016;
2005).
Doorbar, J. 1991. An emerging function for E4. Papillomavirus Rep. 2,
145–148.
Doorbar, J., Myers, G. 1996. The E4 protein. In: Myers, G., Baker,
G., Wheeler, C., Halpern, C., McBride, A., Doorbar, J. (Eds.),
Human Papillomaviruses 1996: A Compilation and Analysis of
Nucleic Acid and Amino Acid Sequences. Theoretical Biology and
Biophysics, Los Alamos National Laboratory, Los Alamos, NM,
pp. III-58– III-80.
Durst, M., Dzarlieva-Petrusevska, R., Boukamp, P., Fusenig, N., Gissmann,
L. 1987. Molecular and cytogenetic analysis of immortalized human
primary keratinocytes obtained after transfection with human papillo-
mavirus type 16 DNA. Oncogene 1, 251–256.
Dyson, N., Howley, P., Munger, K., Harlow, E. 1989. The human papilloma
virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene
product. Science 243, 934–937.
Emeny, R.T., Herron, J.R., Xi, L.F., Koutsky, L.A., Kiviat, N.B., Wheeler,
C.M. 1999. Comparison of variant-specific hybridization and single-
strand conformational polymorphism methods for detection of mixed
human papillomavirus type 16 variant infections. J. Clin. Microbiol. 37,
3627–3633.
Gagnon, S., Hankins, C., Tremblay, C., Forest, P., Pourreaux, K., Coutlee,
F. 2004. Viral polymorphism in human papillomavirus types 33 and 35
and persistent and transient infection in the genital tract of women.
J. Infect. Dis. 190, 1575–1585.
Gagnon, S., Hankins, C., Tremblay, C., Pourreaux, K., Forest, P., Rouah, F.,
Coutlee, F. 2005. Polymorphism of human papillomavirus type 31
isolates infecting the genital tract of HIV-seropositive and HIV-
seronegative women at risk for HIV infection. J. Med. Virol. 75,
213–221.
Hecht, J., Kadish, A., Jiang, G., Burk, R. 1995. Genetic characterization of
the human papillomavirus (HPV) 18 E2 gene in clinical specimens
suggests the presence of a subtype with decreased oncogenic potential.
Int. J. Cancer 60, 369–376.
Hildesheim, A., Hadjimichael, O., Schwartz, P., Wheeler, C., Barnes, W.,
Lowell, D., Willett, J., Schiffman, M. 1999. Risk factors for rapid-onset
cervical cancer. Am. J. Obstet. Gynecol. 180, 571–577.
H. Arias-Pulido et al. / Virology 338 (2005) 22–34 33Icenogle, J., Sathya, P., Miller, D., Tucker, R., Rawls, W. 1991. Nucleotide
and amino acid sequence variation in the L1 and E7 open reading
frames of human papillomavirus type 6 and type 16. Virology 184,
101–107.
Kadish, A., Hagan, R., Ritter, D., Goldberg, G., Romney, S., Kanetsky, P.,
Beiss, B., Burk, R. 1992. Biologic characteristics of specific human
papillomavirus types predicted from morphology of cervical lesions.
Hum. Pathol. 23, 1262–1269.
Kalantari, M., Karlsen, F., Kristensen, G., Holm, R., Hagmar, B.,
Johansson, B. 1998. Disruption of the E1 and E2 reading frames of
HPV 16 in cervical carcinoma is associated with poor prognosis. Int. J.
Gynecol. Pathol. 17, 146–153.
Kim, S.-S., Tam, J.K., Wang, A.-F., Hegde, R.S. 2000. The structural basis
of DNA target discrimination by papillomavirus E2 proteins. J. Biol.
Chem. 275, 31245–31254.
King, L., Tase, T., Twiggs, L., Okagaki, T., Savage, J., Adcock, L., Prem,
K., Carson, L. 1989. Prognostic significance of the presence of human
papillomavirus DNA in patients with invasive carcinoma of the cervix.
Cancer 63, 897–900.
Kirnbauer, R., Booy, F., Cheng, N., Lowy, D., Schiller, J. 1992.
Papillomavirus L1 major capsid protein self-assembles into virus-like
particles that are highly immunogenic. Proc. Natl. Acad. Sci. U.S.A. 89,
12180–12184.
Kirnbauer, R., Hubbert, N., Wheeler, C., Becker, T., Lowy, D., Schiller, J.
1994. A virus-like particle enzyme-linked immunosorbent assay detects
serum antibodies in a majority of women infected with human
papillomavirus type 16. J. Natl. Cancer. Inst. 86, 494–499.
Kitagawa, K., Yoshikawa, H., Onda, T., Kawana, T., Taketani, Y.,
Yoshikura, H., Iwamoto, A. 1996. Genomic organization of human
papillomavirus type 18 in cervical cancer specimens. Jpn. J. Cancer
Res. 87, 263–268.
Kovelman, R., Bilter, G., Glezer, E., Tsou, A., Barbosa, M. 1996. Enhanced
transcriptional activation by E2 proteins from the oncogenic human
papillomaviruses. J. Virol. 70, 7549–7560.
Kristensen, G., Karlsen, F., Jenkins, A., Kaern, J., Abeler, V., Trope, C.
1996. Human papilloma virus has no prognostic significance in cervical
carcinoma. Eur. J. Cancer 32A, 1349–1353.
Kurman, R., Schiffman, M., Lancaster, W., Reid, R., Jenson, A., Temple,
G., Lorincz, A. 1988. Analysis of individual human papillomavirus
types in cervical neoplasia: a possible role for type 18 in rapid
progression. Am. J. Obstet. Gynecol. 159, 293–296.
Leminen, A., Paavonen, J., Vesterinen, E., Wahlstrom, T., Rantala, I.,
Lehtinen, M. 1991. Human papillomavirus types 16 and 18 in
adenocarcinoma of the uterine cervix. Am. J. Clin. Pathol. 95,
647–652.
Lizano, M., Berumen, J., Guido, M., Casas, L., Garcia-Carranca, A.
1997. Association between human papillomavirus type 18 variants
and histopathology of cervical cancer (published erratum appears in
J Natl Cancer Inst 1997 Oct 1;89(19):1460). J. Natl. Cancer. Inst.
89, 1227–1231.
Mantovani, F., Banks, L. 2001. The human papillomavirus E6
protein and its contribution to malignant progression. Oncogene
20, 7874–7887.
Mayrand, M.-H., Coutlee, F., Hankins, C., Lapointe, N., Forest, P.,
de Ladurantaye, M., Roger, M. The Canadian Women’s HIV
Study Group 2000. Detection of human papillomavirus type 16
DNA in consecutive genital samples does not always represent
persistent infection as determined by molecular variant analysis. J.
Clin. Microbiol. 38, 3388–3393.
Meissner, J. 1997. Sequencing errors in references HPV clones. In: Myers,
G., Baker, C., Munger, K., Sverdup, F., McBride, A., Bernard, H.-U.,
Meissner, J. (Eds.), Human Papillomaviruses 1997: A Compilation and
Analysis of Nucleic Acid and Amino Acid Sequences. Theoretical
Biology and Biophysics, Los Alamos National Laboratory, Los Alamos,
NM, pp. III-110–III-123.
Modis, Y., Trus, B.L., Harrison, S.C. 2002. Atomic model of the
papillomavirus capsid. EMBO J. 21, 4754–4762.Munger, K., Phelps, W., Bubb, V., Howley, P., Schlegel, R. 1989. The E6
and E7 genes of the human papillomavirus type 16 together are
necessary and sufficient for transformation of primary human keratino-
cytes. J. Virol. 63, 4417–4421.
Munger, K., Basile, J., Duensing, S., Eichten, A., Gonzalez, S., Grace, M.,
Zacny, V. 2001. Biological activities and molecular targets of the human
papillomavirus E7 oncoprotein. Oncogene 20, 7888–7898.
O’Connor, M., Chan, S.-Y., Bernard, H.-U. 1995. Transcription factor
binding sites in the long control region of genital HPVs. In: Myers, G.,
Bernard, H.-U., Delius, H., Baker, C., Icenogle, J., Halpern, A. (Eds.),
Human Papillomaviruses 1995: A Compilation and Analysis of Nucleic
Acid and Amino Acid Sequences. Theoretical Biology and Biophysics,
Los Alamos National Laboratory, Los Alamos, NM, pp. III-21–III-40.
Ong, C., Chan, S., Campo, M., Fujinaga, K., Mavromara-Nazos, P.,
Labropoulou, V., Pfister, H., Tay, S., ter Meulen, J., Villa, L. 1993.
Evolution of human papillomavirus type 18: an ancient phylogenetic
root in Africa and intratype diversity reflect coevolution with human
ethnic groups. J. Virol. 67, 6424–6431.
Parkin, D., Pisani, P., Ferlay, J. 1999. Estimates of the worldwide incidence
of 25 major cancers in 1990. Int. J. Cancer 80, 827–841.
Peyton, C., Gravitt, P., Hunt, W., Hundley, R., Zhao, M., Apple, R.,
Wheeler, C. 2001. Determinants of genital human papillomavirus
detection in a US population. J. Infect. Dis. 183, 1554–1564.
Pirisi, L., Yasumoto, S., Feller, M., Doniger, J., DiPaolo, J. 1987.
Transformation of human fibroblasts and keratinocytes with human
papillomavirus type 16 DNA. J. Virol. 61, 1061–1066.
Pushko, P., Sasagawa, T., Cuzick, J., Crawford, L. 1994. Sequence variation
in the capsid protein genes of human papillomavirus type 16. J. Gen.
Virol. 75, 911–916.
Reuter, S., Delius, H., Kahn, T., Hofmann, B., zur Hausen, H., Schwarz, E.
1991. Characterization of a novel human papillomavirus DNA in the
cervical carcinoma cell line ME180. J. Virol. 65, 5564–5568.
Roden, R., Kirnbauer, R., Jenson, A., Lowy, D., Schiller, J. 1994a.
Interaction of papillomaviruses with the cell surface. J. Virol. 68,
7260–7266.
Roden, R., Weissinger, E., Henderson, D., Booy, F., Kirnbauer, R.,
Mushinski, J., Lowy, D., Schiller, J. 1994b. Neutralization of bovine
papillomavirus by antibodies to L1 and L2 capsid proteins. J. Virol. 68,
7570–7574.
Romanczuk, H., Thierry, F., Howley, P. 1990. Mutational analysis of cis
elements involved in E2 modulation of human papillomavirus type 16
P97 and type 18 P105 promoters. J. Virol. 64, 2849–2859.
Romanczuk, H., Villa, L., Schlegel, R., Howley, P. 1991. The viral
transcriptional regulatory region upstream of the E6 and E7 genes is a
major determinant of the differential immortalization activities of
human papillomavirus types 16 and 18. J. Virol. 65, 2739–2744.
Rose, B., Thompson, C., Simpson, J., Jarrett, C., Elliott, P., Tattersall, M.,
Dalrymple, C., Cossart, Y. 1995. Human papillomavirus deoxyribo-
nucleic acid as a prognostic indicator in early-stage cervical cancer: a
possible role for type 18. Am. J. Obstet. Gynecol. 173, 1461–1468.
Rose, B., Thompson, C., Zhang, J., Stoeter, M., Stephen, A., Pfister, H.,
Tattersall, M., Cossart, Y. 1997. Sequence variation in the upstream
regulatory region of HPV 18 isolates from cervical cancers. Gynecol.
Oncol. 66, 282–2889.
Rose, B., Steger, G., Dong, X., Thompson, C., Cossart, Y., Tattersall,
M., Pfister, H. 1998. Point mutations in SP1 motifs in the upstream
regulatory region of human papillomavirus type 18 isolates from
cervical cancers increase promoter activity. J. Gen. Virol. 79,
1659–1663.
Saitou, N., Nei, M. 1987. The neighbor-joining method: a new method for
reconstructing phylogenetic trees. Mol. Biol. Evol. 4, 406–425.
Schlegel, R., Phelps, W., Zhang, Y., Barbosa, M. 1988. Quantitative
keratinocyte assay detects two biological activities of human papillo-
mavirus DNA and identifies viral types associated with cervical
carcinoma. EMBO J. 7, 3181–3187.
Schwartz, S.M., Daling, J.R., Shera, K.A., Madeleine, M.M., McKnight, B.,
Galloway, D.A., Porter, P.L., McDougall, J.K. 2001. Human papil-
H. Arias-Pulido et al. / Virology 338 (2005) 22–3434lomavirus and prognosis of invasive cervical cancer: a population-based
study. J. Clin. Oncol. 19, 1906–1915.
Sichero, L., Franco, E., Villa, L. 2005. Different P105 promoter activities
among natural variants of papillomavirus type 18. J. Infect. Dis. 191,
739–742.
Steger, G., Corbach, S. 1997. Dose-dependent regulation of the early
promoter of human papillomavirus type 18 by the viral E2 protein.
J. Virol. 71, 50–58.
Stewart, A., Eriksson, A., Manos, M., Munoz, N., Bosch, F., Peto, J.,
Wheeler, C. 1996. Intratype variation in 12 human papillomavirus
types: a worldwide perspective. J. Virol. 70, 3127–3136.
Tan, S.-H., Bartsch, D., Schwarz, E., Bernard, H.-U. 1998. Nuclear matrix
attachment regions of human papillomavirus type 16 point toward
conservation of these genomic elements in all genital papillomaviruses.
J. Virol. 72, 3610–3622.
Terry, G., Ho, L., Cuzick, J. 1997. Analysis of E2 amino acid variants of
human papillomavirus types 16 and 18 and their associations with lesion
grade and HLA DR/DQ type. Int. J. Cancer 73, 651–655.
Thompson, J., Gibson, T., Plewniak, F., Jeanmougin, F., Higgins, D. 1997.
The CLUSTAL_X windows interface: flexible strategies for multiple
sequence alignment aided by quality analysis tools. Nucleic Acids Res.
25, 4876–4882.
van Muyden, R., ter Harmsel, B., Smedts, F., Hermans, J., Kuijpers, J.,
Raikhlin, N., Petrov, S., Lebedev, A., Ramaekers, F., Trimbos, J.,
Kleter, B., Quint, W. 1999. Detection and typing of human papilloma-
virus in cervical carcinomas in Russian women: a prognostic study.
Cancer 85, 2011–2016.Vernon, S., Unger, E., Miller, D., Lee, D., Reeves, W. 1997.
Association of human papillomavirus type 16 integration in the E2
gene with poor disease-free survival from cervical cancer. Int. J.
Cancer 74, 50–56.
Villa, L., Schlegel, R. 1991. Differences in transformation activity between
HPV-18 and HPV-16 map to the viral LCR-E6-E7 region. Virology 181,
374–377.
Villa, L.L., Sichero, L., Rahal, P., Caballero, O., Ferenczy, A., Rohan, T.,
Franco, E.L. 2000. Molecular variants of human papillomavirus types
16 and 18 preferentially associated with cervical neoplasia. J. Gen.
Virol. 81, 2959–2968.
Walker, J., Bloss, J., Liao, S., Berman, M., Bergen, S., Wilczynski, S. 1989.
Human papillomavirus genotype as a prognostic indicator in carcinoma
of the uterine cervix. Obstet. Gynecol. 74, 781–785.
Werness, B., Levine, A., Howley, P. 1990. Association of human papilloma-
virus types 16 and 18 E6 proteins with p53. Science 248, 76–79.
Wheeler, C., Yamada, T., Hildesheim, A., Jenison, S. 1997. Human
papillomavirus type 16 sequence variants: identification by E6 and L1
lineage-specific hybridization. J. Clin. Microbiol. 35, 11–19.
Yamada, T., Wheeler, C., Halpern, A., Stewart, A., Hildesheim, A.,
Jenison, S. 1995. Human papillomavirus type 16 variant lineages in
United States populations characterized by nucleotide sequence
analysis of the E6, L2, and L1 coding segments. J. Virol. 69,
7743–7753.
Yamada, T., Manos, M., Peto, J., Greer, C., Munoz, N., Bosch, F., Wheeler,
C. 1997. Human papillomavirus type 16 sequence variation in cervical
cancers: a worldwide perspective. J. Virol. 71, 2463–2472.
